BioInsights - Vol 7 Issue 8

CELL & GENE THERAPY INSIGHTS

September 2021 Issue

Vol 7 Issue 8

Download PDF

Featuring

Issue Spotlight: Scale-up and scale-out - what do we really need and how will we get there?
Focus: Global commercial strategies
Focus: Upstream Bioprocessing
Other articles
Webinars

SPOTLIGHT

Scale-up and scale-out - what do we really need and how will we get there?
Co-sponsor

Foreword

Scale-up and scale-out: what do we really need and how will we get there?

Scale-up and scale-out: what do we really need and how will we get there?

Jan Thirkettle
15 October 2021
Read

Editorial

Improving the yield of rAAV manufacturing with HeLa producer cells lines to ensure patient access

Improving the yield of rAAV manufacturing with HeLa producer cells lines to ensure patient access

Matthew Fuller
5 October 2021
Read

Expert Insight

Scalable downstream process development for <em>in vivo</em> gene therapy products: understanding full/empty separation capabilities and challenges with ion exchange chromatography

Scalable downstream process development for in vivo gene therapy products: understanding full/empty separation capabilities and challenges with ion exchange chromatography

Kumar Dhanasekharan
29 September 2021
Read

Innovator Insight

cGMP manufacturing made easy: a case study by ElevateBio

cGMP manufacturing made easy: a case study by ElevateBio

Michael Paglia, Shannon Eaker
24 November 2021
Read
Scaling-up the production of stem cell-derived extracellular vesicles in stirred-tank bioreactors

Scaling-up the production of stem cell-derived extracellular vesicles in stirred-tank bioreactors

Aurélie Tacheny
29 September 2021
Read
Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Yongchang Ji
14 September 2021
Read

Interview

Reaping the benefits in scalability: the flexibility of an in-house gene therapy manufacturing strategy

Reaping the benefits in scalability: the flexibility of an in-house gene therapy manufacturing strategy

Alexandria Forbes, PhD
15 October 2021
Read
Scaling up viral vector production: the importance of quality

Scaling up viral vector production: the importance of quality

Jeffrey Lacouchie
5 October 2021
Read
Industrializing viral vector manufacture

Industrializing viral vector manufacture

Daniel Teasley, Katherine Schewe
15 September 2021
Read

Expert Roundtable Video

Expert Roundtable: evolution in AAV process development: 2022 and beyond

Expert Roundtable: evolution in AAV process development: 2022 and beyond

A Becerra, M Hebben, M Mercaldi
11 October 2021
Watch
Expert Roundtable: overcoming challenges in analytical assays for cellular therapies

Expert Roundtable: overcoming challenges in analytical assays for cellular therapies

J Joedicke, E Alonzo, M Mues
11 October 2021
Watch

Expert Roundtable

Expert Roundtable: overcoming challenges in analytical assays for cellular therapies

Expert Roundtable: overcoming challenges in analytical assays for cellular therapies

J Joedicke, E Alonzo, M Mues
13 October 2021
Read
Expert Roundtable: evolution in AAV process development: 2022 and beyond

Expert Roundtable: evolution in AAV process development: 2022 and beyond

12 October 2021
Read

FastFacts

Cell and gene manufacturing: a case study approach to overcoming challenges – understanding the value of an expert supplier

Cell and gene manufacturing: a case study approach to overcoming challenges – understanding the value of an expert supplier

Sean Werner, Adam Shields
4 October 2021
Read
Getting closer to the in vivo environment with human AB serum

Getting closer to the in vivo environment with human AB serum

Trevor Smith
31 August 2021
Read

Viewpoint

From start-up to scale-up: a journey through AAV process development

From start-up to scale-up: a journey through AAV process development

Kevin Mouillesseaux
5 October 2021
Read
Viral vector gene delivery: balancing safety, efficacy and dose

Viral vector gene delivery: balancing safety, efficacy and dose

Thijs Gerritzen
1 October 2021
Read

Supply Chain FOCUS

Global commercial strategies

On Demand Webinar

Importance of high-quality starting material for success in advanced therapy

Importance of high-quality starting material for success in advanced therapy

R Amareld, N MS, J Lin et al.
12 August 2021
Read

Interview

Evolution and innovation in autologous cell therapy supply chain

Evolution and innovation in autologous cell therapy supply chain

Sadia L’Baouch
18 August 2021
Read

Vectors FOCUS

Upstream Bioprocessing

FastFacts

Development of a scalable AAV production process in suspension cells

Development of a scalable AAV production process in suspension cells

Ann-Christin Magnusson
11 November 2021
Read
Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies

Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies

Yasser Kehail
5 October 2021
Read
Achieving cost-effective, scalable high-titer AAV production

Achieving cost-effective, scalable high-titer AAV production

Chao Yan Liu
30 September 2021
Read
Addressing HEK293 cell lineage and AAV diversity with media panel

Addressing HEK293 cell lineage and AAV diversity with media panel

Jennifer Schieber
29 September 2021
Read
Scale up of a lentiviral production process from the iCELLis<sup>®️</sup> Nano Bioreactor to the iCELLis 500+ Bioreactor

Scale up of a lentiviral production process from the iCELLis®️ Nano Bioreactor to the iCELLis 500+ Bioreactor

Isabelle Pelletier, Kaitlynn Bayne
22 September 2021
Read
Scalable cell culture and transient transfection for viral vector manufacturing

Scalable cell culture and transient transfection for viral vector manufacturing

Ann Rossi Bilodeau
20 September 2021
Read

Innovator Insight

Transfer and scale-up from 10 L BioBLU<sup>®️</sup> to Allegro™ STR 50 and STR 200 Bioreactors

Transfer and scale-up from 10 L BioBLU®️ to Allegro™ STR 50 and STR 200 Bioreactors

D Mainwaring, A Joshi, J Coronel et al.
25 November 2021
Read
Key considerations for maximizing LV and AAV production in transient transfection workflows

Key considerations for maximizing LV and AAV production in transient transfection workflows

L Kopp, B Larimore, A Dasgupta
8 October 2021
Read
Utilizing a media panel rapidly accelerates media optimization for AAV manufacturers

Utilizing a media panel rapidly accelerates media optimization for AAV manufacturers

Céline Martin, Jennifer Zatina
28 September 2021
Read
Scalability comparison between 50 and 500 liter stirred tank bioreactor for production of rAAV viral vector

Scalability comparison between 50 and 500 liter stirred tank bioreactor for production of rAAV viral vector

T Sanderson, T Erlandson, N Hazi et al.
23 September 2021
Read
Evaluation of a microbioreactor system as a screening tool for optimizing lentiviral vector process development in suspension culture

Evaluation of a microbioreactor system as a screening tool for optimizing lentiviral vector process development in suspension culture

N Sutherland, L Chan, K Kral et al.
22 September 2021
Read

Commentary

Enabling development of commercial-ready lentiviral vector manufacturing processes using stable producer cell lines

Enabling development of commercial-ready lentiviral vector manufacturing processes using stable producer cell lines

Peter Archibald, Ph.D, Anthony Shillings
22 September 2021
Read

Viewpoint

Overview of major AAV production platforms

Overview of major AAV production platforms

Jote Bulcha
24 September 2021
Read

Journal articles

Interview

Broadening horizons for extracellular vesicles as both therapeutic modality and delivery tool

Broadening horizons for extracellular vesicles as both therapeutic modality and delivery tool

Joana Correia
17 August 2021
Read
Evolving technology trends and regulatory pathways in the tissue engineered product space

Evolving technology trends and regulatory pathways in the tissue engineered product space

William Fodor
17 August 2021
Read

FastFacts

Adenovirus vector manufacturing platform using CIMmultus™️ QA assures the supply of safe vaccines

Adenovirus vector manufacturing platform using CIMmultus™️ QA assures the supply of safe vaccines

Hana Jug
4 October 2021
Read

Webinars